WO1993010121A1 - Epothilones, process for preparing the same and their use as medicaments and as plant protecting agents - Google Patents
Epothilones, process for preparing the same and their use as medicaments and as plant protecting agents Download PDFInfo
- Publication number
- WO1993010121A1 WO1993010121A1 PCT/EP1992/002656 EP9202656W WO9310121A1 WO 1993010121 A1 WO1993010121 A1 WO 1993010121A1 EP 9202656 W EP9202656 W EP 9202656W WO 9310121 A1 WO9310121 A1 WO 9310121A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- epothilones
- methanol
- merck
- epothilone
- hydrogen
- Prior art date
Links
- 229930013356 epothilone Natural products 0.000 title claims abstract description 31
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 title claims abstract description 30
- 239000003814 drug Substances 0.000 title claims description 3
- 238000004519 manufacturing process Methods 0.000 title abstract description 5
- 239000003223 protective agent Substances 0.000 title description 2
- 150000003883 epothilone derivatives Chemical class 0.000 claims abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 66
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 13
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 12
- 239000011347 resin Substances 0.000 claims description 8
- 229920005989 resin Polymers 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 6
- 229910052782 aluminium Inorganic materials 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 claims description 6
- 239000011888 foil Substances 0.000 claims description 6
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 150000002500 ions Chemical class 0.000 claims description 6
- 238000010791 quenching Methods 0.000 claims description 6
- 230000000171 quenching effect Effects 0.000 claims description 6
- 235000012141 vanillin Nutrition 0.000 claims description 6
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 6
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 230000001472 cytotoxic effect Effects 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 206010062016 Immunosuppression Diseases 0.000 claims description 2
- 238000003898 horticulture Methods 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 230000001506 immunosuppresive effect Effects 0.000 claims description 2
- 238000001953 recrystallisation Methods 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims 2
- 239000006229 carbon black Substances 0.000 claims 1
- 230000000855 fungicidal effect Effects 0.000 claims 1
- 239000000417 fungicide Substances 0.000 claims 1
- 230000001408 fungistatic effect Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000012050 conventional carrier Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- LMSDCGXQALIMLM-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;iron Chemical compound [Fe].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O LMSDCGXQALIMLM-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000907556 Mucor hiemalis Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 241001532577 Sorangium Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical class C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
Definitions
- the invention relates to epothilones of the following general formula:
- R 1 is hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkanoyl, Li + , K + , Na + , 1/2 Mg 2+ or 1/2 Ca 2+ and R 2 is hydrogen or one Represents methyl group.
- the invention further relates to an epothilone, characterized by one or more of the following parameters:
- the invention further relates to an epothilone, characterized by one or more of the following parameters:
- V 3400; 2958; 2931; 2875; 1735; 1689: 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm -1
- Epothilones with the following structural formula are particularly preferred:
- the invention further relates to a method for obtaining epothilones, in particular the epothilones characterized above, which is characterized in that the strain So ce90 DSM 6773 - in a carbon containing nitrogen sources and mineral salts
- Adsorber resin is added, - the fermenter broth is separated, - the epothilones are extracted from the adsorber resin and - the eluates are removed directly or via further cleaning steps from the / the
- Recrystallization purifies and separates the different epothilones.
- the epothilones obtained in this way can be reacted further using common chemical processes, e.g. converted with bases into the alkali and alkaline earth salts and, if appropriate, further converted to ethers, or they can be converted into the corresponding esters with organic acids.
- the invention further relates to an agent for crop protection in agriculture
- Forestry and / or horticulture consisting of one or more of the above-mentioned epothilones or containing one or more of these epothilones, optionally in addition to one or more conventional carriers and / or diluents.
- the invention relates to a therapeutic agent which can in particular develop cytotoxic activities and / or cause immunosuppression, consisting of one or more of the above-mentioned epothilones or containing one or more of these epothilones, optionally in addition to one or more conventional carriers and / or Diluent (s).
- GEF German Collection of Microorganisms
- the stem grows on cellulose as the only carbon and energy source with KNO 3 as the only nitrogen source, e.g. on filter paper over ST21 mineral salt agar (0.1% KNO 3 ; 0.1% MgSO 4 ⁇ 7 H 2 0; 0.1% CaCI 2 ⁇ 2 H 2 O; 0.1% K 2 HPO 4 ; 0.01% MnSO 4 ⁇ 7 H 2 O; 0.02% FeCI 3 ; 0.002% yeast extract; standard trace element solution; 1% agar). Be on this medium
- dark red-brown to black-brown fruiting bodies formed, consisting of small sporangioles (about 15 to 30 ⁇ m in diameter) in more or less large, dense clusters and packages.
- the strain grows very well with glucose and KNO 3 , e.g. on CA2 agar (basic medium: 1.5 g agar in 92 ml distilled water; stock solution 1: 7.5% KNO 3 , 7.5% K 2 HPO 4 in distilled water; stock solution 2: 1.5% MgSO 4 ⁇ 7 H 2 O in distilled water; stock solution 3: 0.2% CaCl 2 ⁇ 2 H 2 O, 0.15% FeCl 3 in distilled water; stock solution 4: 20% glucose in distilled water.
- the stock solutions are autoclaved 1 ml of solutions 1 to 3 and 5 ml of solution 4 are added to the basic medium, as well as a suitable amount of a trace element solution).
- the vegetative rods have the shape typical of Sorangium (relatively coarse, cylindrical, dark in the phase contrast microscope with broadly rounded ends, on average 3 - 6 ⁇ m long and 1 ⁇ m thick). After a longer adaptation to the growth in liquid media, the strain grows in a homogeneous cell suspension.
- a typical fermentation proceeds as follows: A 100 l fermenter is mixed with 60 l medium (0.8% starch; 0.2% glucose; 0.2% soy flour; 0.2% yeast extract; 0.1% CaCl 2 ⁇ 2 H 2 O; 0.1% MgSO 4 ⁇ 7 H 2 O; 8 mg / l Fe-EDTA; pH 7.4) filled. Inoculation is carried out with 10 l of a preculture (160 rpm, 30 ° C.) which has been grown in the same medium but additionally with 50 mM HEPES buffer pH 7.4 in shake flasks.
- the fermentation takes place at 32 oC with a stirring speed of 500 rpm and aeration of 0.2. NL per m 3 and hour, the pH is kept at 7.4 by adding KOH. The fermentation takes 7-10 days.
- the active compounds formed are partly in the supernatant and partly in the cells.
- fermentation can be carried out in the presence of adsorber resins (e.g. XAD-1180, Rohm and Haas, 2 - 5%).
- adsorber resins e.g. XAD-1180, Rohm and Haas, 2 - 5%.
- Sora ⁇ gium cellulosum So ce90 e.g. 70 I
- the crude extract is taken up in 50 ml of methanol and isocratic with Lichroprep RP-18 25-40 ⁇ m (column: 400 ⁇ 100 mm; flow: 200 ml / min; Merck Prepbar)
- Epothilon B ethyl acetate
Abstract
Epothilones having general formula (I), a process for preparing the same and epothilone-containing agents are disclosed.
Description
EPOTHILONE, DEREN HERSTELLUNGSVERFAHREN UND IHRE VERWENDUNG ALS ARZNEIMITTEL UND PFLANZENSCHUTZENDE MITTEL EPOTHILONES, THEIR PRODUCTION PROCESS AND THEIR USE AS MEDICINAL PRODUCTS AND PLANT PROTECTIVE AGENTS
Die Erfindung betrifft Epothilone der folgenden allgemeinen Formel: The invention relates to epothilones of the following general formula:
worin R1 Wasserstoff, C1-C4-Alkyl, C1-C4-Alkanoyl, Li+, K+, Na+, 1/2 Mg2+ oder 1/2 Ca2+ bedeutet und R2 Wasserstoff oder eine Methylgruppe darstellt. wherein R 1 is hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkanoyl, Li + , K + , Na + , 1/2 Mg 2+ or 1/2 Ca 2+ and R 2 is hydrogen or one Represents methyl group.
Ferner betrifft die Erfindung ein Epothilon, gekennzeichnet durch einen oder mehrere der folgenden Parameter:
The invention further relates to an epothilone, characterized by one or more of the following parameters:
FAB-MS (neg. Ionen): 492.25 für (M - H)- FAB-MS (neg. Ions): 492.25 for (M - H) -
UV (MeOH) λmax (log ε) = 210 (4.17); 249 (3.97) UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97)
IR Film auf Irtran: IR film on Irtran:
v: 3429:2966; 2937; 1737; 1691; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm-1 v: 3429: 2966; 2937; 1737; 1691; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm -1
DC: RF = 0,75 DC: R F = 0.75
DC-Alufolie 60 F254, Merck; Laufmittel: TLC aluminum foil 60 F 254 , Merck; Solvent:
Dichlormethan/Methanol = 90 : 10 Dichloromethane / methanol = 90:10
Detektion: 1. UV-Löschung bei 254 nm Detection: 1. UV quenching at 254 nm
2. Ansprühen mit Vanillin/Schwefelsäure-Reagenz und erhitzen auf 120 °C, braune Anfärbung 2. Spray on with vanillin / sulfuric acid reagent and heat to 120 ° C, brown color
HPLC: Rt = 5,4 min HPLC: R t = 5.4 min
Säule: 4 × 250 mm Lichrosorb RP-187 μm, Merck; Column: 4 × 250 mm Lichrosorb RP-187 μm, Merck;
Fluß: 1 ,5 ml/min; Laufmittel: Methanol/Wasser = 65 : 35 Flow: 1.5 ml / min; Mobile solvent: methanol / water = 65: 35
Detektor: UV 254 nm Detector: UV 254 nm
Des weiteren betrifft die Erfindung ein Epothilon, gekennzeichnet durch einen oder mehrere der folgenden Parameter:
The invention further relates to an epothilone, characterized by one or more of the following parameters:
FAB-MS (neg. Ionen): 506.25 für (M - H)- FAB-MS (neg. Ions): 506.25 for (M - H) -
UV (MeOH) λmax (log ε) = 210 (4.17); 249 (3.97) UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97)
IR Film auf Irtran: IR film on Irtran:
V = 3400; 2958; 2931; 2875; 1735; 1689: 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm-1 V = 3400; 2958; 2931; 2875; 1735; 1689: 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm -1
DC: RF = 0,75 DC: R F = 0.75
DC-Alufolie 60 F254, Merck; Laufmittel: TLC aluminum foil 60 F 254 , Merck; Solvent:
Dichlormethan/Methanol = 90 : 10 Dichloromethane / methanol = 90:10
Detektion: 1. UV-Löschung bei 254 nm Detection: 1. UV quenching at 254 nm
2. Ansprühen mit Vanillin/Schwefelsäure-Reagenz und erhitzt auf 120 ºC, braune Anfärbung 2. Spray on with vanillin / sulfuric acid reagent and heat to 120 ºC, brown color
HPLC: Rt = 6,3 min HPLC: R t = 6.3 min
Säule: 4 × 250 mm Lichrosorb RP-187 μm, Merck; Column: 4 × 250 mm Lichrosorb RP-187 μm, Merck;
Fluß: 1 ,5 ml/min; Laufmittel: Methanol/Wasser = 65 : 35 Flow: 1.5 ml / min; Mobile solvent: methanol / water = 65: 35
Detektor: UV 254 nm Detector: UV 254 nm
Besonders bevorzugt sind Epothilone mit der folgenden Strukturformel: Epothilones with the following structural formula are particularly preferred:
worin R2 Wasserstoff oder Methyl bedeutet. (Das Kohlenstoffatom der Methyigruppe wird als C27 bezeichnet). Ferner betrifft die Erfindung ein Verfahren zum Gewinnen von Epothilonen, insbesondere der vorstehend charakterisierten Epothilone, das dadurch gekennzeichnet ist, daß man den Stamm So ce90 DSM 6773 - in einem Kohlenstoffquellen, Stickstoffquellen und Mineralsalze enthaltenden wherein R 2 is hydrogen or methyl. (The carbon atom of the methyl group is called C27). The invention further relates to a method for obtaining epothilones, in particular the epothilones characterized above, which is characterized in that the strain So ce90 DSM 6773 - in a carbon containing nitrogen sources and mineral salts
Medium kultiviert, - entweder während der Kultivierung des Stammes oder anschließend ein Medium cultivated, - either during the cultivation of the strain or afterwards
Adsorberharz zusetzt, - die Fermenterbrühe abtrennt, - die Epothilone aus dem Adsorberharz efuiert und - die Eluate direkt oder über weitere Reinigungsschritte von dem/den Adsorber resin is added, - the fermenter broth is separated, - the epothilones are extracted from the adsorber resin and - the eluates are removed directly or via further cleaning steps from the / the
Lösungsmittel (n) befreit, - und gegebenenfalls über Hochdruck/Niederdruckchromatographie und/oder Solvent (s) freed - and if necessary via high pressure / low pressure chromatography and / or
Umkristallisation die verschiedenen Epothilone aufreinigt und voneinander trennt. Recrystallization purifies and separates the different epothilones.
Gegebenenfalls können die so gewonnenen Epothilone mit gängigen chemischen Verfahren weiter umgesetzt werden, z.B. mit Basen in die Alkali- und Erdalkalisalze überführt und gegebenenfalls weiter zu Ethem umgesetzt werden, oder sie können mit organischen Säuren in die entsprechenden Ester überführt werden. If necessary, the epothilones obtained in this way can be reacted further using common chemical processes, e.g. converted with bases into the alkali and alkaline earth salts and, if appropriate, further converted to ethers, or they can be converted into the corresponding esters with organic acids.
Ferner betrifft die Erfindung ein Mittel für den Pflanzenschutz in Landwirtschaft, The invention further relates to an agent for crop protection in agriculture,
Forstwirtschaft und/oder Gartenbau, bestehend aus einem oder mehreren der vorstehend aufgeführten Epothilone oder eines oder mehrere dieser Epothilone enthaltend, gegebenenfalls neben einem oder mehreren üblichen Träger(n) und/oder Verdünnungsmittel(n).
Schließlich betrifft die Erfindung ein therapeutisches Mittel, das insbesondere cytotoxische Aktivitäten entwickeln und/oder Immunsuppression bewirken kann, bestehend aus einem oder mehreren der vorstehend aufgeführten Epothilone oder eines oder mehrere dieser Epothilone enthaltend, gegebenenfalls neben einem oder mehreren üblichen Träger(n) und/oder Verdünnungsmittel(n). Forestry and / or horticulture consisting of one or more of the above-mentioned epothilones or containing one or more of these epothilones, optionally in addition to one or more conventional carriers and / or diluents. Finally, the invention relates to a therapeutic agent which can in particular develop cytotoxic activities and / or cause immunosuppression, consisting of one or more of the above-mentioned epothilones or containing one or more of these epothilones, optionally in addition to one or more conventional carriers and / or Diluent (s).
- Administrationsform: oral - Administration form: oral
- Dosis 0.5 bis 200 mg für einen Menschen mit 70 kg Normalgewicht - Dose 0.5 to 200 mg for a person with a normal weight of 70 kg
- Verwendungszweck: Antitumor - Intended use: anti-tumor
Im folgenden wird die Erfindung anhand von Beispielen und experimentellen Daten näher erläutert. The invention is explained in more detail below with the aid of examples and experimental data.
Produktionsstamm Production master
Stamm So ce90 wurde im Juli 1985 an der Gesellschaft für Biotechnologische Strain So ce90 was born in July 1985 at the Society for Biotechnological
Forschung (GBF) aus einer Bodenprobe von den Ufern des Zambesi, im südlichen Afrika, isoliert. Der Stamm ist bei der Deutschen Sammlung von Mikroorganismen (DSM) unter Nr. 6773 hinterlegt. Research (GBF) isolated from a soil sample from the banks of the Zambesi, in southern Africa. The strain is deposited with the German Collection of Microorganisms (DSM) under No. 6773.
Stammkultur und morphologische Beschreibung: Der Stamm wächst auf Cellulose als einziger Kohlenstoff- und Energiequelle mit KNO3 als einzige Stickstoffquelle, z.B. auf Filterpapier über ST21 Mineralsalzagar (0.1 % KNO3; 0.1 % MgSO4 × 7 H20; 0.1 % CaCI2 × 2 H2O; 0.1% K2HPO4; 0.01 % MnSO4 × 7 H2O; 0.02% FeCI3; 0.002% Hefeextrakt; Standard-Spurenelementlösung; 1% Agar). Auf diesem Medium werden Strain culture and morphological description: The stem grows on cellulose as the only carbon and energy source with KNO 3 as the only nitrogen source, e.g. on filter paper over ST21 mineral salt agar (0.1% KNO 3 ; 0.1% MgSO 4 × 7 H 2 0; 0.1% CaCI 2 × 2 H 2 O; 0.1% K 2 HPO 4 ; 0.01% MnSO 4 × 7 H 2 O; 0.02% FeCI 3 ; 0.002% yeast extract; standard trace element solution; 1% agar). Be on this medium
dunkelrotbraune bis schwarzbraune Fruchtkörper gebildet, bestehend aus kleinen Sporangiolen (etwa 15 bis 30 μm Durchmesser) in mehr oder weniger großen dichten Haufen und Paketen. dark red-brown to black-brown fruiting bodies formed, consisting of small sporangioles (about 15 to 30 μm in diameter) in more or less large, dense clusters and packages.
Der Stamm wächst sehr gut mit Glucose und KNO3, z.B. auf CA2-Agar (Grundmedium: 1.5 g Agar in 92 ml Aqua dest.; Stammlösung 1 : 7.5% KNO3, 7.5% K2HPO4 in Aqua dest; Stammiösung 2: 1.5% MgSO4 × 7 H2O in Aqua dest; Stammlösung 3: 0.2% CaCI2 × 2 H2O, 0.15% FeCl3 in Aqua dest.; Stammlösung 4: 20% Glucose in Aqua dest. Die Stammiösungen werden durch Autoklavieren sterilisiert. Je 1 ml der Lösungen 1 bis 3, sowie 5 ml der Lösung 4 werden dem Grundmedium zugegeben, ebenso eine geeignete Menge einer Spurenelementlösung).
Die vegetativen Stäbchen haben die für Sorangium typische Form (relativ derbe, im Phasenkontrastmikroskop dunkle, zylindrische Stäbchen mit breit abgerundeten Enden, im Mittel 3 - 6 μm lang und 1 μm dick). Nach längerer Adaptation an das Wachstum in Flüssigmedien wächst der Stamm in homogener Zeilsuspension. The strain grows very well with glucose and KNO 3 , e.g. on CA2 agar (basic medium: 1.5 g agar in 92 ml distilled water; stock solution 1: 7.5% KNO 3 , 7.5% K 2 HPO 4 in distilled water; stock solution 2: 1.5% MgSO 4 × 7 H 2 O in distilled water; stock solution 3: 0.2% CaCl 2 × 2 H 2 O, 0.15% FeCl 3 in distilled water; stock solution 4: 20% glucose in distilled water. The stock solutions are autoclaved 1 ml of solutions 1 to 3 and 5 ml of solution 4 are added to the basic medium, as well as a suitable amount of a trace element solution). The vegetative rods have the shape typical of Sorangium (relatively coarse, cylindrical, dark in the phase contrast microscope with broadly rounded ends, on average 3 - 6 μm long and 1 μm thick). After a longer adaptation to the growth in liquid media, the strain grows in a homogeneous cell suspension.
Der Stamm So ce90 produziert chemisch nahe verwandte Verbindungen, die The So ce90 strain produces chemically closely related compounds that
antibiotische Aktivität besitzen. Insbesondere sind diese Verbindungen cytotoxisch sowie antifungal wirksam. Hervorzuheben ist z.B. die Hemmung von Mucor hiemalis. have antibiotic activity. In particular, these compounds are cytotoxic and antifungal. It should be emphasized e.g. the inhibition of Mucor hiemalis.
Produktion der biologisch aktiven Verbindungen: Production of the biologically active compounds:
Die Verbindungen werden während der iogarithmischen bis hin zur stationären The connections are made during the logarithmic to the stationary
Wachstumsphase produziert. Eine typische Fermentation verläuft folgendermaßen: Ein 100 l-Fermenter wird mit 60 I Medium (0.8% Stärke; 0.2% Glucose; 0.2% Soyamehl; 0.2% Hefeextrakt; 0.1% CaCI2 × 2 H2O; 0.1% MgSO4 × 7 H2O; 8 mg/l Fe-EDTA; pH 7.4) gefüllt. Beimpft wird mit 10 I einer im gleichen Medium jedoch zusätzlich mit 50 mM HEPES-Puffer pH 7.4 in Schüttelkolben angezogenen Vorkultur (160 upm, 30 ºC). Growth phase produced. A typical fermentation proceeds as follows: A 100 l fermenter is mixed with 60 l medium (0.8% starch; 0.2% glucose; 0.2% soy flour; 0.2% yeast extract; 0.1% CaCl 2 × 2 H 2 O; 0.1% MgSO 4 × 7 H 2 O; 8 mg / l Fe-EDTA; pH 7.4) filled. Inoculation is carried out with 10 l of a preculture (160 rpm, 30 ° C.) which has been grown in the same medium but additionally with 50 mM HEPES buffer pH 7.4 in shake flasks.
Fermentiert wird bei 32 ºC mit einer Rührgeschwindigkeit von 500 upm und einer Belüftung von 0.2. NL pro m3 und Std, der pH Wert wird durch Zugabe von KOH bei 7.4 gehalten. Die Fermentation dauert 7 - 10 Tage. Die gebildeten aktiven Verbindungen befinden sich teils im Überstand und teils in den Zellen. The fermentation takes place at 32 ºC with a stirring speed of 500 rpm and aeration of 0.2. NL per m 3 and hour, the pH is kept at 7.4 by adding KOH. The fermentation takes 7-10 days. The active compounds formed are partly in the supernatant and partly in the cells.
Alternativ dazu kann in Gegenwart von Adsorberharzen (z.B. XAD-1180, Rohm und Haas, 2 - 5 %) fermentiert werden. Alternatively, fermentation can be carried out in the presence of adsorber resins (e.g. XAD-1180, Rohm and Haas, 2 - 5%).
Isolierung von Epothilon A und B Isolation of epothilones A and B
Während der Fermentation von Soraπgium cellulosum So ce90 (z.B. 70 I During the fermentation of Soraπgium cellulosum So ce90 (e.g. 70 I
Fermentationsvolumen) in Gegenwart eines Adsorberharzes (z.B.: XAD-1180, Röhm und Haas, 2 % v/v) werden die gebildeten Antibiotika Epothilon A (Abb. 1 ) und B (Abb. 2) vollständig an das Harz gebunden. Nach Abtrennung der Kulturbrühe (z.B. durch Absieben in einem Prozeßfilter) wird das Harz mit 3 Bettvolumen Wasser gewaschen und mit 4 Bettvolumen Methanol eluiert. Die vereinigten Eluate werden im Vakuum bis auf den Wassergehalt eingeengt und dreimal mit je 0.2 1 Ethylacetat extrahiert. Die vereinigten Ethylacetatextrakte werden zur Trockne eingeengt (ca. 40 g Fermentation volume) in the presence of an adsorber resin (e.g. XAD-1180, Röhm and Haas, 2% v / v), the antibiotics Epothilon A (Fig. 1) and B (Fig. 2) are completely bound to the resin. After the culture broth has been separated off (e.g. by sieving in a process filter), the resin is washed with 3 bed volumes of water and eluted with 4 bed volumes of methanol. The combined eluates are concentrated in vacuo to the water content and extracted three times with 0.2 l of ethyl acetate each time. The combined ethyl acetate extracts are evaporated to dryness (approx. 40 g
Trockengewicht).
Der Rohextrakt wird in 50 ml Methanol aufgenommen und an Lichroprep RP-18 25-40 μm (Säule: 400 × 100 mm; Fluß: 200 ml/min; Merck Prepbar) isokratisch mit Dry weight). The crude extract is taken up in 50 ml of methanol and isocratic with Lichroprep RP-18 25-40 μm (column: 400 × 100 mm; flow: 200 ml / min; Merck Prepbar)
Methanol/Wasser 6/4 chromatographiert. Die Epothilone enthaltenden Fraktionen (Rt ca. 95 - 125 min) werden durch RP-18 Niederdruckchromatographie aufgereinigt. (Säule 400 × 60; HD-Sil-18-20-60, Labomatic; Laufmittel: Methanol/Wasser 65/35; Fluß 25 ml/min; Rt Epothilon A: 140 - 165 min; Rt Epothilon B: 170 - 195 min). Chromatographed methanol / water 6/4. The fractions containing epothilones (R t approx. 95-125 min) are purified by RP-18 low pressure chromatography. (Column 400 × 60; HD-Sil-18-20-60, Labomatic; mobile solvent: methanol / water 65/35; flow 25 ml / min; R t epothilone A: 140 - 165 min; R t epothilone B: 170 - 195 min).
Die Feinreinigung der Epothilone erfolgt durch Kristallisation aus The epothilones are cleaned out by crystallization
1. Epothilon A: Toluol/Ethyiacetat = 3 : 2 1. Epothilone A: toluene / ethyl acetate = 3: 2
2. Epothilon B: Ethylacetat 2. Epothilon B: ethyl acetate
Epothilon A Epothilone A
C26H39NO6S [493] C 26 H 39 NO 6 S [493]
FAB-MS (neg. Ionen): 492.25 für (M - H)- FAB-MS (neg. Ions): 492.25 for (M - H) -
1H-NMR-Daten s. Tab. 1 1 H-NMR data see. Tab. 1
13C-NMR-Daten s. Tab. 2 13 C-NMR data see. Tab. 2
UV (MeOH) λmax (log ε) = 210 (4.17); 249 (3.97) UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97)
IR Film auf Irtran: IR film on Irtran:
ν: 3429:2966:2937; 1737; 1691; 1463: 1374; 1295; 1257; 1185; 1150; 1087; 1029: 1014:979 CITT1 ν: 3429: 2966: 2937; 1737; 1691; 1463: 1374; 1295; 1257; 1185; 1150; 1087; 1029: 1014: 979 CITT 1
DC: RF = 0,75 DC: R F = 0.75
DC-Alufolie 60 F254, Merck; Laufmittel: TLC aluminum foil 60 F 254 , Merck; Solvent:
Dichlormethan/Methanol = 90 : 10 Dichloromethane / methanol = 90:10
Detektion: 1. UV-Löschung bei 254 nm Detection: 1. UV quenching at 254 nm
2. Ansprühen mit Vanillin/Schwefelsäure-Reagenz und erhitzen auf 120 ºC, braune Anfärbung 2. Spray on with vanillin / sulfuric acid reagent and heat to 120 ºC, brown color
HPLC: Rt = 5,4 min HPLC: R t = 5.4 min
Säule: 4 × 250 mm Lichrosorb RP-18 7 μm, Merck; Column: 4 × 250 mm Lichrosorb RP-18 7 μm, Merck;
Fluß: 1 ,5 ml/min; Laufmittel: Methanol/Wasser = 65 : 35 Flow: 1.5 ml / min; Mobile solvent: methanol / water = 65: 35
Detektor: UV 254 nm
Epothilon B Detector: UV 254 nm Epothilon B
C27H41NO6S [507] C 27 H 41 NO 6 S [507]
FAB-MS (neg. Ionen): 506.25 für (M - H)- 1H-NMR-Daten s. Tab. 1 FAB-MS (neg. Ions): 506.25 for (M - H) - 1 H NMR data see. Tab. 1
13C-NMR-Daten s. Tab. 2 1 3 C-NMR data see. Tab. 2
UV (MeOH) λmax (log ε) = 210 (4.17); 249 (3.97) UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97)
IR Film auf lrtran: IR film on lrtran:
ν = 3400:2958: 2931: 2875: 1735: 1689: 1629: 1609: 1463: 1378: 1250; 1149: 1049; 977 cm-1 ν = 3400: 2958: 2931: 2875: 1735: 1689: 1629: 1609: 1463: 1378: 1250; 1149: 1049; 977 cm -1
DC: RF = 0,75 DC: R F = 0.75
DC-Alufolie 60 F254, Merck; Laufmittel: TLC aluminum foil 60 F 254 , Merck; Solvent:
Dichiormethan/Methanol = 90 : 10 Dichloromethane / methanol = 90:10
Detektion: 1. UV-Löschung bei 254 nm Detection: 1. UV quenching at 254 nm
2. Ansprühen mit Vanillin/Schwefelsäure-Reagenz und erhitzt auf 120 ºC, braune Anfärbung 2. Spray on with vanillin / sulfuric acid reagent and heat to 120 ºC, brown color
HPLC: Rt = 6,3 min HPLC: R t = 6.3 min
Säule: 4 × 250 mm Lichrosorb RP-187 μm, Merck; Column: 4 × 250 mm Lichrosorb RP-187 μm, Merck;
Fluß: 1,5 mi/min; Laufmittel: Methanol/Wasser = 65 : 35 Flow: 1.5 mi / min; Mobile solvent: methanol / water = 65: 35
Detektor: UV 254 nm
Detector: UV 254 nm
Nach bekannten Methoden (T. Meyer, U. Renegass, D. Fabbro, E. Alten, J. Rösel, M. Müller, G. Caravatti & A. Matter: A derivative of staurosporine (CGP 41 251 ) shows selectivity for protein kinase C inhibition and in vitro anti-prol iterative as well as in vivo anti-tumor activity. Int. J. Cancer 1989, 43, 851-6) wird Epothilon A auf die Hemmung der T-24 Zellinie untersucht. Es wird ein IC50 Wert von < 0.05 μM ermittelt.
According to known methods (T. Meyer, U. Renegass, D. Fabbro, E. Alten, J. Rösel, M. Müller, G. Caravatti & A. Matter: A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-prol iterative as well as in vivo anti-tumor activity. Int. J. Cancer 1989, 43, 851-6), epothilone A is examined for the inhibition of the T-24 cell line. An IC 50 value of <0.05 μM is determined.
Claims
1. Epothilone der allgemeinen Formel: 1. Epothilone of general formula:
worin R1 Wasserstoff, C1-C4-Alkyl, C1-C4-Acyl, Li+, K+, Na+, 1/2 Mg2+ oder 1/2 Ca2+ bedeutet und R2 Wasserstoff oder eine Methylgruppe darstellt. where R 1 is hydrogen, C 1 -C 4 alkyl, C 1 -C 4 acyl, Li + , K + , Na +, 1/2 Mg 2+ or 1/2 Ca 2+ and R 2 is hydrogen or a methyl group represents.
2. Epothilone der allgemeinen Formel: 2. Epothilones of general formula:
worin R2 Wasserstoff oder Methyl ist where R 2 is hydrogen or methyl
3. Epothilon, gekennzeichnet durch einen oder mehrere der folgenden Parameter:
C26H39NO6S [493] 3. Epothilone, characterized by one or more of the following parameters: C26H39NO6S [ 493 ]
FAB-MS (neg. Ionen): 492.25 für (M - H)- FAB-MS (neg. ions): 492.25 for (M - H)-
UV (MeOH) λmax (log ε) = 210 (4.17); 249 (3.97) UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97)
IR Film auf Irtran: IR film on Irtran:
v: 3429; 2966; 2937; 1737; 1691 ; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm-1 v: 3429; 2966; 2937; 1737; 1691 ; 1463; 1374; 1295; 1257; 1185; 1150; 1087; 1029; 1014; 979 cm -1
DC: RF = 0,75 TLC: R F = 0.75
DC-Alufolie 60 F254, Merck; Laufmittel: DC aluminum foil 60 F 254 , Merck; Mobile solvent:
Dϊchiormethan/Methanol = 90 : 10 Dichloromethane/methanol = 90:10
Detektion: 1. UV-Löschung bei 254 nm Detection: 1. UV quenching at 254 nm
2. Ansprühen mit Vanillin/Schwefelsäure-Reagenz und erhitzen auf 120 *C, braune Anfärbung 2. Spray with vanillin/sulfuric acid reagent and heat to 120 * C, brown color
HPLC: Rt = 5,4 min HPLC: R t = 5.4 min
Säule: 4 × 250 mm Lichrosorb RP-187 μm, Merck: Column: 4 × 250 mm Lichrosorb RP-187 μm, Merck:
Fluß: 1,5 ml/min: Laufmittel: Methanol/Wasser = 65 : 35 Flow: 1.5 ml/min: mobile phase: methanol/water = 65:35
Detektor: UV 254 nm Detector: UV 254 nm
4. Epothilon, gekennzeichnet durch einen oder mehrere der folgenden Parameter:
4. Epothilone, characterized by one or more of the following parameters:
FAB-MS (neg. Ionen): 506.25 für (M - H)- FAB-MS (neg. ions): 506.25 for (M - H)-
UV (MeOH) λmax (log ε) = 210 (4.17); 249 (3.97) UV (MeOH) λ max (log ε) = 210 (4.17); 249 (3.97)
IR Film auf Irtran: IR film on Irtran:
v = 3400; 2958:2931, 2875; 1735; 1689; 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm-1 v = 3400; 2958:2931, 2875; 1735; 1689; 1629; 1609; 1463; 1378; 1250; 1149; 1049; 977 cm -1
DC: RF = 0,75 TLC: R F = 0.75
DC-Alufolie 60 F254, Merck; Laufmittel: DC aluminum foil 60 F254, Merck; Mobile solvent:
Dichlormethan/Methanol = 90 : 10 Dichloromethane/methanol = 90:10
Detektion: 1. UV-Löschung bei 254 nm Detection: 1. UV quenching at 254 nm
2. Ansprühen mit Vanillin/Schwefelsäure-Reagenz und erhitzt auf 120 ºC, braune Anfärbung 2. Spraying with vanillin/sulfuric acid reagent and heated to 120 ºC, brown color
HPLC: Rt = 6,3 min HPLC: R t = 6.3 min
Säule: 4 × 250 mm Lichrosorb RP-187 μm, Merck; Column: 4 × 250 mm Lichrosorb RP-187 μm, Merck;
Ruß: 1 ,5 ml/min; Laufmittel: Methanol/Wasser= 65 : 35 Carbon black: 1.5 ml/min; Mobile phase: methanol/water = 65:35
Detektor: UV 254 nm
Detector: UV 254 nm
5. Verfahren zum Herstellen von Epothilonen nach einem der vor anstehenden 5. Process for producing epothilones according to one of the above
Ansprüche, dadurch gekennzeichnet, daß man den Stamm So ce90 - in einem Kohlenstoffquellen, Stickstoffquellen und Mineralsalze enthaltenden Medium kultiviert, - entweder während der Kultivierung des Stammes oder anschließend ein Claims, characterized in that the So ce90 strain is cultivated in a medium containing carbon sources, nitrogen sources and mineral salts, either during the cultivation of the strain or subsequently
Adsorberharz zusetzt, - die Fermenterbrühe abtrennt, - die Epothilone aus dem Adsorberharz eluiert und - die Eluate direkt oder über weitere Reinigungsschritte von dem/den Adsorber resin is added, - the fermenter broth is separated, - the epothilones are eluted from the adsorber resin and - the eluates are removed directly or via further purification steps
Lösungsmittel(n) befreit, - und gegebenenfalls über Hochdruck/Niederdruckchromatographie und/oder Solvent(s) freed, - and if necessary via high pressure/low pressure chromatography and/or
Umkristailisation die verschiedenen Epothilone aufreinigt und voneinander trennt. Recrystallization purifies the different epothilones and separates them from each other.
6. Mittel für den Pflanzenschutz in der Landwirtschaft und Forstwirtschaft und/oder im Gartenbau, bestehend aus einem oder mehreren Epothilonen gemäß einem der voranstehenden Ansprüche oder eines oder mehrerer dieser Epothilone enthaltend, gegebenenfalls neben einem oder mehreren üblichen Träger(n) und/oder 6. Agents for plant protection in agriculture and forestry and/or in horticulture, consisting of one or more epothilones according to one of the preceding claims or containing one or more of these epothilones, optionally in addition to one or more usual carriers and/or
Verdünnungsmittel(n). Diluent(s).
7. Mittel nach Anspruch 6, dadurch gekennzeichnet, daß es ein Fungizid oder Fungistatikum ist. 7. Agent according to claim 6, characterized in that it is a fungicide or fungistatic.
8. Therapeutisches Mittel, das insbesondere cytotoxische Aktivitäten entwickeln und/oder Immunsuppresion bewirken kann, bestehend aus einem oder mehreren Epothilonen nach einem der Ansprüche 1 bis 4 oder diese Epothilone enthaltend, gegebenenfalls neben einem oder mehreren üblichen Träger(n) und/oder 8. Therapeutic agent which can in particular develop cytotoxic activities and/or cause immunosuppression, consisting of one or more epothilones according to one of claims 1 to 4 or containing these epothilones, optionally in addition to one or more usual carriers and/or
Verdünnungsmittel(n).
Diluent(s).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19914138042 DE4138042C2 (en) | 1991-11-19 | 1991-11-19 | Epothilones, their production processes and agents containing these compounds |
DEP4138042.8 | 1991-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993010121A1 true WO1993010121A1 (en) | 1993-05-27 |
Family
ID=6445140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1992/002656 WO1993010121A1 (en) | 1991-11-19 | 1992-11-19 | Epothilones, process for preparing the same and their use as medicaments and as plant protecting agents |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2943792A (en) |
DE (1) | DE4138042C2 (en) |
WO (1) | WO1993010121A1 (en) |
Cited By (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997019086A1 (en) * | 1995-11-17 | 1997-05-29 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone derivatives, preparation and use |
WO1998008849A1 (en) * | 1996-08-30 | 1998-03-05 | Novartis Aktiengesellschaft | Method for producing epothilones, and intermediate products obtained during the production process |
WO1998022461A1 (en) * | 1996-11-18 | 1998-05-28 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents |
WO1998038192A1 (en) * | 1997-02-25 | 1998-09-03 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilones with a modified side chain |
WO1999028324A1 (en) * | 1997-12-04 | 1999-06-10 | Bristol-Myers Squibb Company | A process for the reduction of oxiranyl epothilones to olefinic epothilones |
WO1999039694A2 (en) * | 1998-02-05 | 1999-08-12 | Novartis Ag | Compositions containing organic compounds |
WO1999042602A2 (en) * | 1998-02-19 | 1999-08-26 | Novartis Ag | Fermentative preparation process for cytostatics and crystal forms thereof |
FR2775187A1 (en) * | 1998-02-25 | 1999-08-27 | Novartis Ag | Treatment of proliferative diseases, especially drug-resistant cancers - with epothilone B |
WO1999058534A2 (en) * | 1998-05-08 | 1999-11-18 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone derivatives, a method for the production thereof, and their use |
EP0987268A1 (en) * | 1998-08-05 | 2000-03-22 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilone A-N-oxide, epothilone B-N-oxide, process for their preparation and agent containing same |
US6043372A (en) * | 1996-08-30 | 2000-03-28 | Novartis Ag | Intermediates in the process for preparing epothilones |
WO2000023452A1 (en) * | 1998-10-14 | 2000-04-27 | Schering Aktiengesellschaft | Method for producing epothilone b and derivatives, and intermediate products for this method |
US6121029A (en) * | 1998-06-18 | 2000-09-19 | Novartis Ag | Genes for the biosynthesis of epothilones |
EP1035824A1 (en) * | 1997-12-04 | 2000-09-20 | Bristol-Myers Squibb Company | A process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
JP2001504856A (en) * | 1996-12-13 | 2001-04-10 | ノヴァルティス アクチェンゲゼルシャフト | Epothilone analogues |
US6262094B1 (en) | 1999-02-22 | 2001-07-17 | Bristol-Myers Squibb Company | C-21 modified epothilones |
WO2001060976A1 (en) * | 2000-02-17 | 2001-08-23 | Novartis Ag | Single colonies of myxobacteria cells |
US6291684B1 (en) | 1999-03-29 | 2001-09-18 | Bristol-Myers Squibb Company | Process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
US6302838B1 (en) | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
US6303342B1 (en) | 1998-11-20 | 2001-10-16 | Kason Biosciences, Inc. | Recombinant methods and materials for producing epothilones C and D |
US6320045B1 (en) | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
US6380395B1 (en) | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
WO2002046196A1 (en) * | 2000-12-07 | 2002-06-13 | Novartis Ag | Process for the isolation and purification of epothilones |
US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
US6576651B2 (en) | 2001-01-25 | 2003-06-10 | Bristol-Myers Squibb Company | Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones |
US6589968B2 (en) | 2001-02-13 | 2003-07-08 | Kosan Biosciences, Inc. | Epothilone compounds and methods for making and using the same |
US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
US6596875B2 (en) | 2000-02-07 | 2003-07-22 | James David White | Method for synthesizing epothilones and epothilone analogs |
US6603023B2 (en) | 1996-12-03 | 2003-08-05 | Sloan Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
WO2003078411A1 (en) | 2002-03-12 | 2003-09-25 | Bristol-Myers Squibb Company | C3-cyano epothilone derivatives |
US6660758B1 (en) | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
US6670384B2 (en) | 2001-01-25 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
US6686380B2 (en) | 2001-02-20 | 2004-02-03 | Bristol-Myers Squibb Company | Treatment of refractory tumors using epothilone derivatives |
US6689802B2 (en) | 2000-08-16 | 2004-02-10 | Bristol-Myers Squibb Company | Polymorphs of an epothilone analog |
EP1386922A3 (en) * | 1996-12-03 | 2004-04-07 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereof, analogues and uses thereof |
US6727276B2 (en) | 2001-02-20 | 2004-04-27 | Bristol-Myers Squibb Company | Epothilone derivatives for the treatment of refractory tumors |
US6780620B1 (en) | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
US6800653B2 (en) | 2001-06-01 | 2004-10-05 | Bristol-Myers Squibb Compnay | Epothilone derivatives |
WO2005030767A1 (en) * | 2003-09-26 | 2005-04-07 | Wolfgang Richter | Novel macrocycles for treating tumor diseases |
US6884608B2 (en) | 2001-12-26 | 2005-04-26 | Bristol-Myers Squibb Company | Compositions and methods for hydroxylating epothilones |
US6893859B2 (en) | 2001-02-13 | 2005-05-17 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
EP1542998A2 (en) * | 2002-09-23 | 2005-06-22 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b |
US6936628B2 (en) | 2002-04-04 | 2005-08-30 | Bristol-Myers Squibb Company | Oral administration of epothilones |
US7008936B2 (en) | 2002-06-14 | 2006-03-07 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
US7022330B2 (en) | 2001-01-25 | 2006-04-04 | Bristol-Myers Squibb Company | Parenteral formulation for epothilone analogs |
US7053069B2 (en) | 2002-05-15 | 2006-05-30 | Bristol-Myers Squibb Company | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
US7153864B2 (en) | 2000-03-17 | 2006-12-26 | Cell Therapeutics Inc. | Polyglutamic acid-camptothecin conjugates and methods of preparation |
CN1312286C (en) * | 2005-10-19 | 2007-04-25 | 华南理工大学 | Method for highly-effective producing epothilone using myxobacteria sorangium cellulosum |
US7211593B2 (en) | 2002-03-12 | 2007-05-01 | Bristol-Myers Squibb Co. | C12-cyano epothilone derivatives |
EP1800664A1 (en) * | 1998-02-05 | 2007-06-27 | Novartis AG | Pharmaceutical formulations for parenteral administration comprising epothilone |
WO2007117439A2 (en) | 2006-03-31 | 2007-10-18 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
US7312237B2 (en) | 2001-03-14 | 2007-12-25 | Bristol-Myers Squibb Co. | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
EP2030618A2 (en) | 2002-01-14 | 2009-03-04 | Novartis AG | Combinations comprising epothilones and anti-metabolites |
EP2065054A1 (en) | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Combinations comprising a prostaglandin and uses thereof |
EP2070521A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Surface-modified nanoparticles |
DE102007059752A1 (en) | 2007-12-10 | 2009-06-18 | Bayer Schering Pharma Aktiengesellschaft | Functionalized solid polymer nanoparticles containing epothilones |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
WO2010040252A1 (en) * | 2008-10-06 | 2010-04-15 | 山东大学 | Epothilone glycoside compounds, compositions containing epothilone glycoside compounds as active components and uses thereof |
US7723339B2 (en) | 2001-02-27 | 2010-05-25 | Novartis Ag | Combination comprising a signal transduction inhibitor and an epothilone derivative |
EP2210584A1 (en) | 2009-01-27 | 2010-07-28 | Bayer Schering Pharma Aktiengesellschaft | Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer |
EP2210643A2 (en) | 2001-07-19 | 2010-07-28 | Novartis AG | Combinations comprising epothilones and pharmaceutical uses thereof |
EP2241566A1 (en) * | 2008-02-01 | 2010-10-20 | Zhejiang Hisun Pharmaceutical Co. Ltd. | A method for the separation and purification of epothilones |
US7932031B2 (en) | 2004-11-30 | 2011-04-26 | Bristol-Myers Squibb Company | Methods for determining sensitivity to microtubule-stabilizing agents comprising ixabepilone by measuring the level of estrogen receptor 1 |
US8143415B2 (en) | 2007-05-25 | 2012-03-27 | Bristol-Myers Squibb Company | Processes for making epothilone compounds and analogs |
CN103145722A (en) * | 2013-03-05 | 2013-06-12 | 福建省微生物研究所 | Method for separating and purifying epothilone by high-speed counter-current chromatography |
US8618146B2 (en) | 2011-01-03 | 2013-12-31 | Dr. Reddy's Laboratories Limited | Epothilone compound formulations |
WO2015024884A1 (en) * | 2013-08-19 | 2015-02-26 | Sandoz Ag | Method for the purifiction of epothilones via crystallization |
EP3566719A1 (en) | 2010-05-18 | 2019-11-13 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19636343C1 (en) * | 1996-08-30 | 1997-10-23 | Schering Ag | New (di:methyl)-dioxanyl-methyl-pentanone and related compounds |
EP1847540A1 (en) | 1997-08-09 | 2007-10-24 | Bayer Schering Pharma Aktiengesellschaft | Nouveaux dérivés d'épothilone, leur procédé de production et leur utilisation pharmaceutique |
US7001916B1 (en) | 1999-02-11 | 2006-02-21 | Schering, Ag | Epothilon derivatives, method for the production and the use thereof as pharmaceuticals |
ID30460A (en) | 1999-04-15 | 2001-12-06 | Bristol Myers Squibb Co | INHIBITORS, INHIBITORS, THYROCIN CINASE PROTEIN |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US7125893B1 (en) | 1999-04-30 | 2006-10-24 | Schering Ag | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
MXPA03002521A (en) | 2000-09-22 | 2004-02-12 | Biotechnolog Forschung Gmbh | Triazolo-epothilones. |
EP1767535B1 (en) | 2002-08-23 | 2009-12-02 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
EP1567487A4 (en) | 2002-11-15 | 2005-11-16 | Bristol Myers Squibb Co | Open chain prolyl urea-related modulators of androgen receptor function |
US20050171167A1 (en) | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
DE10355223A1 (en) | 2003-11-26 | 2005-06-30 | Institut für Pflanzenbiochemie (IPB) | New macrocycles for the treatment of cancer |
US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
AU2007329375A1 (en) | 2006-12-04 | 2008-06-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to treat cancer with cupredoxins and CpG rich DNA |
CN102863474A (en) | 2011-07-09 | 2013-01-09 | 陈小平 | Platinum compounds for treating cell proliferative diseases and preparation method and application thereof |
CN102993239A (en) | 2011-09-19 | 2013-03-27 | 陈小平 | Platinum compound of succinic acid derivative with leaving group containing amino or alkylamino |
CN104768962B (en) | 2012-11-17 | 2017-04-05 | 北京市丰硕维康技术开发有限责任公司 | Leaving group is the platinum-like compounds of the malonate derivative containing amino or alkylamino |
-
1991
- 1991-11-19 DE DE19914138042 patent/DE4138042C2/en not_active Expired - Lifetime
-
1992
- 1992-11-19 AU AU29437/92A patent/AU2943792A/en not_active Abandoned
- 1992-11-19 WO PCT/EP1992/002656 patent/WO1993010121A1/en active Application Filing
Non-Patent Citations (1)
Title |
---|
CHEMICAL ABSTRACTS, vol. 93, no. 7, 18. August 1980, Columbus, Ohio, US; abstract no. 72218v, Y. SHIMAUCHI ET AL. 'Deltamycin antibiotics' Seite 1025 ; * |
Cited By (192)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1440973A3 (en) * | 1995-11-17 | 2004-10-20 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilone derivatives, preparation and use |
EP1186606A1 (en) * | 1995-11-17 | 2002-03-13 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilone derivatives, their preparation and utilization |
WO1997019086A1 (en) * | 1995-11-17 | 1997-05-29 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone derivatives, preparation and use |
US6288237B1 (en) | 1995-11-17 | 2001-09-11 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Epothilons C and D, preparation and compositions |
EP0903348A1 (en) * | 1995-11-17 | 1999-03-24 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Epothilone derivatives, preparation and utilization |
US6831076B2 (en) | 1995-11-17 | 2004-12-14 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Epothilons C and D, preparation and compositions |
US6613912B2 (en) | 1995-11-17 | 2003-09-02 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Epothilons C and D, preparation and compositions |
EP1440973A2 (en) * | 1995-11-17 | 2004-07-28 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilone derivatives, preparation and use |
US6884817B2 (en) | 1996-03-12 | 2005-04-26 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US7384977B2 (en) | 1996-03-12 | 2008-06-10 | Pg-Txl Company, L.P. | Water soluble paclitaxel prodrugs |
US7135496B2 (en) | 1996-03-12 | 2006-11-14 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US7060724B2 (en) | 1996-03-12 | 2006-06-13 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US6043372A (en) * | 1996-08-30 | 2000-03-28 | Novartis Ag | Intermediates in the process for preparing epothilones |
US6156905A (en) * | 1996-08-30 | 2000-12-05 | Novartis Ag | Deoxy epothilones and intermediates utilized in the process for preparing epothilones |
WO1998008849A1 (en) * | 1996-08-30 | 1998-03-05 | Novartis Aktiengesellschaft | Method for producing epothilones, and intermediate products obtained during the production process |
CZ303422B6 (en) * | 1996-11-18 | 2012-09-05 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone C, process for its preparation and its use as cytostatic and plant protection composition |
WO1998022461A1 (en) * | 1996-11-18 | 1998-05-28 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents |
KR100538095B1 (en) * | 1996-11-18 | 2005-12-21 | 게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) | Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents |
US7846952B2 (en) | 1996-11-18 | 2010-12-07 | Helmholtz-Zentrum Fuer Infektionsforschung Gmbh | Epothilones C, D, E, and F, preparation and compositions |
CN100344627C (en) * | 1996-11-18 | 2007-10-24 | 生物技术研究有限公司(Gbf) | Epothilones C, and its preparation and use as cell inhibitor |
AU753546B2 (en) * | 1996-11-18 | 2002-10-24 | Helmholtz-Zentrum Fuer Infektionsforschung Gmbh | Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents |
EP1367057A1 (en) * | 1996-11-18 | 2003-12-03 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilones C, E and F |
US8076490B2 (en) | 1996-11-18 | 2011-12-13 | Helmholtz-Zentrum Fuer Infektionsforschung Gmbh | Epothilones C, D, E, and F, preparation and compositions |
USRE41990E1 (en) | 1996-12-03 | 2010-12-07 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
EP1386922A3 (en) * | 1996-12-03 | 2004-04-07 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereof, analogues and uses thereof |
US6603023B2 (en) | 1996-12-03 | 2003-08-05 | Sloan Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6828340B2 (en) | 1996-12-03 | 2004-12-07 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6723854B2 (en) | 1996-12-03 | 2004-04-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
JP2001504856A (en) * | 1996-12-13 | 2001-04-10 | ノヴァルティス アクチェンゲゼルシャフト | Epothilone analogues |
US7173137B2 (en) * | 1996-12-13 | 2007-02-06 | The Scripps Research Institute | Epothilone analogs |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
US6660758B1 (en) | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
US6359140B1 (en) | 1997-02-25 | 2002-03-19 | Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) | Epothilones with modified side chain |
WO1998038192A1 (en) * | 1997-02-25 | 1998-09-03 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilones with a modified side chain |
CZ298027B6 (en) * | 1997-02-25 | 2007-05-30 | Gesellschaft Fuer Biotechnologische Forschung Mbh(Gbf) | Process for preparing epothilone-N-oxides and N-oxides of epothilones per se |
EP1201666A2 (en) * | 1997-02-25 | 2002-05-02 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilones with a modified side chain |
US8536327B2 (en) | 1997-07-08 | 2013-09-17 | Bristol-Myers Squibb Company | Epothilone derivatives |
USRE43003E1 (en) | 1997-07-08 | 2011-12-06 | Bristol-Myers Squibb Company | Epothilone derivatives |
USRE41893E1 (en) | 1997-07-08 | 2010-10-26 | Bristol-Myers Squibb Company | Epothilone derivatives |
CN100384834C (en) * | 1997-07-08 | 2008-04-30 | 布里斯托尔-迈尔斯斯奎布公司 | Epothilone derivatives |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
USRE41911E1 (en) | 1997-07-08 | 2010-11-02 | Bristol-Myers Squibb Company | Epothilone derivatives |
USRE41895E1 (en) | 1997-07-08 | 2010-10-26 | Bristol-Myers Squibb Company | Epothilone derivatives |
US8921542B2 (en) | 1997-07-08 | 2014-12-30 | Bristol-Myers Squibb Company | Epothilone derivatives |
US7125899B2 (en) | 1997-07-08 | 2006-10-24 | Bristol-Myers Squibb Company | Epothilone derivatives |
US7241755B2 (en) | 1997-07-08 | 2007-07-10 | Bristol-Myers Squibb Company | Epothilone derivatives |
US6320045B1 (en) | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
WO1999028324A1 (en) * | 1997-12-04 | 1999-06-10 | Bristol-Myers Squibb Company | A process for the reduction of oxiranyl epothilones to olefinic epothilones |
EP1035824A1 (en) * | 1997-12-04 | 2000-09-20 | Bristol-Myers Squibb Company | A process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
EP1035824A4 (en) * | 1997-12-04 | 2001-10-24 | Bristol Myers Squibb Co | A process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
JP4644364B2 (en) * | 1998-02-05 | 2011-03-02 | ノバルティス アーゲー | Epothilone composition |
CZ303168B6 (en) * | 1998-02-05 | 2012-05-09 | Novartis Ag | Pharmaceutical composition |
AU753519B2 (en) * | 1998-02-05 | 2002-10-17 | Novartis Ag | Compositions containing organic compounds |
WO1999039694A3 (en) * | 1998-02-05 | 1999-09-23 | Novartis Ag | Compositions containing organic compounds |
JP2002502810A (en) * | 1998-02-05 | 2002-01-29 | ノバルティス アクチエンゲゼルシャフト | Epothilone composition |
CN100396276C (en) * | 1998-02-05 | 2008-06-25 | 诺瓦提斯公司 | Compositions containing organic compounds |
EP1800664A1 (en) * | 1998-02-05 | 2007-06-27 | Novartis AG | Pharmaceutical formulations for parenteral administration comprising epothilone |
BE1012140A3 (en) * | 1998-02-05 | 2000-05-02 | Novartis Ag | Organic compounds. |
WO1999039694A2 (en) * | 1998-02-05 | 1999-08-12 | Novartis Ag | Compositions containing organic compounds |
FR2774909A1 (en) * | 1998-02-05 | 1999-08-20 | Novartis Ag | PHARMACEUTICAL FORMULATION, INFUSION SOLUTION AND LYOPHILIZED COMPOSITION COMPRISING EPOTHILONE. |
KR100873526B1 (en) * | 1998-02-19 | 2008-12-11 | 노파르티스 아게 | Fermentative preparation Process for Cytostatics and Crystal Forms Thereof |
WO1999042602A3 (en) * | 1998-02-19 | 1999-11-25 | Novartis Ag | Fermentative preparation process for cytostatics and crystal forms thereof |
AU746294B2 (en) * | 1998-02-19 | 2002-04-18 | Novartis Ag | Fermentative preparation process for cytostatics and crystal forms thereof |
WO1999042602A2 (en) * | 1998-02-19 | 1999-08-26 | Novartis Ag | Fermentative preparation process for cytostatics and crystal forms thereof |
US6380227B1 (en) | 1998-02-19 | 2002-04-30 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
EP1428826A2 (en) * | 1998-02-19 | 2004-06-16 | Novartis AG | Crystal forms of cytostatics |
US6656711B2 (en) | 1998-02-19 | 2003-12-02 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
EP1428826A3 (en) * | 1998-02-19 | 2004-10-27 | Novartis AG | Crystal forms of cytostatics |
CZ301517B6 (en) * | 1998-02-19 | 2010-03-31 | Novartis Ag | Process for concentrating epothilones, culture medium therefor and process for preparing epothilones |
US7101702B2 (en) | 1998-02-19 | 2006-09-05 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
JP2005068156A (en) * | 1998-02-19 | 2005-03-17 | Novartis Ag | Fermentative preparation process and crystal form of cytostatic |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
US7875601B2 (en) | 1998-02-25 | 2011-01-25 | Novartis Ag | Cancer treatment with epothilones |
FR2775187A1 (en) * | 1998-02-25 | 1999-08-27 | Novartis Ag | Treatment of proliferative diseases, especially drug-resistant cancers - with epothilone B |
WO1999043320A1 (en) * | 1998-02-25 | 1999-09-02 | Novartis Ag | Use of epothilones for the treatment of cancer |
BE1011980A5 (en) * | 1998-02-25 | 2000-03-07 | Novartis Ag | Cancer treatment with epothilones. |
US6302838B1 (en) | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
US7091226B2 (en) | 1998-02-25 | 2006-08-15 | Novartis Ag | Cancer treatment with epothilones |
US6399638B1 (en) | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
US6831090B2 (en) | 1998-04-21 | 2004-12-14 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
US6380395B1 (en) | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
WO1999058534A2 (en) * | 1998-05-08 | 1999-11-18 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone derivatives, a method for the production thereof, and their use |
US6982280B1 (en) | 1998-05-08 | 2006-01-03 | Gerhard Hoefle | Epothilone derivatives, a method for the production thereof, and their use |
AU754212B2 (en) * | 1998-05-08 | 2002-11-07 | Gesellschaft Fur Biotechnologische Forschung Mbh | Epothilone derivatives, a method for the production thereof, and their use |
WO1999058534A3 (en) * | 1998-05-08 | 2000-01-13 | Biotechnolog Forschung Gmbh | Epothilone derivatives, a method for the production thereof, and their use |
US6355459B1 (en) | 1998-06-18 | 2002-03-12 | Novartis Ag | Genes for the biosynthesis of epothilones |
US6358719B1 (en) | 1998-06-18 | 2002-03-19 | Novartis Ag | Genes for the biosynthesis of epothilones |
US6121029A (en) * | 1998-06-18 | 2000-09-19 | Novartis Ag | Genes for the biosynthesis of epothilones |
US6858404B2 (en) | 1998-06-18 | 2005-02-22 | Novartis Ag | Genes for the biosynthesis of epothilones |
US6346404B1 (en) | 1998-06-18 | 2002-02-12 | Novartis Ag | Genes for the biosynthesis of epothilones |
US6355457B1 (en) | 1998-06-18 | 2002-03-12 | Novartis Ag | Genes for the biosynthesis of epothilones |
US6355458B1 (en) | 1998-06-18 | 2002-03-12 | Novartis Ag | Genes for the biosynthesis of epothilones |
US6383787B1 (en) | 1998-06-18 | 2002-05-07 | Novartis Ag | Genes for the biosynthesis of epothilones |
US7579366B2 (en) | 1998-06-22 | 2009-08-25 | The Scripps Research Institute | Epothilone derivatives and their synthesis and use |
US6531497B1 (en) | 1998-06-22 | 2003-03-11 | The Scripps Research Institute | Epothilone derivatives and their synthesis and use |
EP0987268A1 (en) * | 1998-08-05 | 2000-03-22 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilone A-N-oxide, epothilone B-N-oxide, process for their preparation and agent containing same |
US6605726B1 (en) | 1998-10-14 | 2003-08-12 | Schering Ag | Method for producing epothilone B and derivatives, and intermediate products for this method |
WO2000023452A1 (en) * | 1998-10-14 | 2000-04-27 | Schering Aktiengesellschaft | Method for producing epothilone b and derivatives, and intermediate products for this method |
US6303342B1 (en) | 1998-11-20 | 2001-10-16 | Kason Biosciences, Inc. | Recombinant methods and materials for producing epothilones C and D |
US7732186B2 (en) | 1998-11-20 | 2010-06-08 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
US7402421B2 (en) | 1998-11-20 | 2008-07-22 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
US6921650B1 (en) | 1998-11-20 | 2005-07-26 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
US7129071B1 (en) | 1998-11-20 | 2006-10-31 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
US6583290B1 (en) | 1998-11-20 | 2003-06-24 | Kosam Biosciences, Inc. | 14-methyl epothilone derivatives |
US6858411B1 (en) | 1998-11-20 | 2005-02-22 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
US7067286B2 (en) | 1998-11-20 | 2006-06-27 | Kosan Biosciences, Inc. | Cystobacterineae host cells containing heterologous PKS genes for the synthesis of polykedtides |
US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
US7244594B2 (en) | 1998-12-23 | 2007-07-17 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
US6780620B1 (en) | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
US6958401B2 (en) | 1999-02-05 | 2005-10-25 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Method for synthesizing epothilones and epothilone analogs |
US7145018B2 (en) | 1999-02-05 | 2006-12-05 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The Oregon State University | Method for synthesizing epothilones and epothilone analogs |
US6262094B1 (en) | 1999-02-22 | 2001-07-17 | Bristol-Myers Squibb Company | C-21 modified epothilones |
US6291684B1 (en) | 1999-03-29 | 2001-09-18 | Bristol-Myers Squibb Company | Process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
US6596875B2 (en) | 2000-02-07 | 2003-07-22 | James David White | Method for synthesizing epothilones and epothilone analogs |
WO2001060976A1 (en) * | 2000-02-17 | 2001-08-23 | Novartis Ag | Single colonies of myxobacteria cells |
US7153864B2 (en) | 2000-03-17 | 2006-12-26 | Cell Therapeutics Inc. | Polyglutamic acid-camptothecin conjugates and methods of preparation |
US7173041B2 (en) | 2000-03-17 | 2007-02-06 | Cell Therapeutics Inc. | Polyglutamic acid-camptothecin conjugates and methods of preparation |
USRE39356E1 (en) * | 2000-03-20 | 2006-10-17 | Bristol-Myers Squibb Co. | Process for the preparation of epothilone analogs |
US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
USRE39251E1 (en) * | 2000-08-16 | 2006-08-29 | Bristol-Myers Squibb Co. | Polymorphs of an epothilone analog |
US6982276B2 (en) | 2000-08-16 | 2006-01-03 | Bristol-Myers Squibb Company | Polymorphs of an epothilone analog |
BG66132B1 (en) * | 2000-08-16 | 2011-06-30 | Bristol-Myers Squibb Company | Polymorphs of an epothilone analog |
LT5138B (en) | 2000-08-16 | 2004-06-25 | Bristol-Myers Squibb Company | Polymorphs of an epothilone analog |
US7153879B2 (en) | 2000-08-16 | 2006-12-26 | Bristol-Myers Squibb Company | Polymorphs of an epothilone analog |
US6689802B2 (en) | 2000-08-16 | 2004-02-10 | Bristol-Myers Squibb Company | Polymorphs of an epothilone analog |
US6946561B2 (en) | 2000-12-07 | 2005-09-20 | Novartis Ag | Process for the isolation and purification of epothilones |
US7569698B2 (en) | 2000-12-07 | 2009-08-04 | Novartis Ag | Process for the isolation and purification of epothilones |
WO2002046196A1 (en) * | 2000-12-07 | 2002-06-13 | Novartis Ag | Process for the isolation and purification of epothilones |
KR100894990B1 (en) * | 2000-12-07 | 2009-04-24 | 노파르티스 아게 | Process for the isolation and purification of epothilones |
CZ301664B6 (en) * | 2000-12-07 | 2010-05-19 | Novartis Ag | Method of desorption and obtaining epothilones A, B, D, E and/or F and use of weakly polar or apolar solvent for desorption of epothilones A, B, D, E and/or F from a resin |
US7022330B2 (en) | 2001-01-25 | 2006-04-04 | Bristol-Myers Squibb Company | Parenteral formulation for epothilone analogs |
US8632788B2 (en) | 2001-01-25 | 2014-01-21 | Bristol-Myers Squibb Company | Parenteral formulation for epothilone analogs |
US6670384B2 (en) | 2001-01-25 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
USRE40387E1 (en) * | 2001-01-25 | 2008-06-17 | Bristol-Myers Squibb Company | Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones |
EP1938821A2 (en) | 2001-01-25 | 2008-07-02 | Bristol-Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
US6576651B2 (en) | 2001-01-25 | 2003-06-10 | Bristol-Myers Squibb Company | Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones |
US6893859B2 (en) | 2001-02-13 | 2005-05-17 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
US6589968B2 (en) | 2001-02-13 | 2003-07-08 | Kosan Biosciences, Inc. | Epothilone compounds and methods for making and using the same |
US7176235B2 (en) | 2001-02-13 | 2007-02-13 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
US6727276B2 (en) | 2001-02-20 | 2004-04-27 | Bristol-Myers Squibb Company | Epothilone derivatives for the treatment of refractory tumors |
USRE41393E1 (en) | 2001-02-20 | 2010-06-22 | Bristol-Myers Squibb Company | Treatment of refractory tumors using epothilone derivatives |
US6686380B2 (en) | 2001-02-20 | 2004-02-03 | Bristol-Myers Squibb Company | Treatment of refractory tumors using epothilone derivatives |
US7723339B2 (en) | 2001-02-27 | 2010-05-25 | Novartis Ag | Combination comprising a signal transduction inhibitor and an epothilone derivative |
US7312237B2 (en) | 2001-03-14 | 2007-12-25 | Bristol-Myers Squibb Co. | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
US8598215B2 (en) | 2001-03-14 | 2013-12-03 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
US8569347B2 (en) | 2001-03-14 | 2013-10-29 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
US6800653B2 (en) | 2001-06-01 | 2004-10-05 | Bristol-Myers Squibb Compnay | Epothilone derivatives |
EP2210643A2 (en) | 2001-07-19 | 2010-07-28 | Novartis AG | Combinations comprising epothilones and pharmaceutical uses thereof |
US7214527B2 (en) | 2001-12-26 | 2007-05-08 | Bristol-Myers Squibb Company | Compositions and methods for hydroxylating epothilones |
US6884608B2 (en) | 2001-12-26 | 2005-04-26 | Bristol-Myers Squibb Company | Compositions and methods for hydroxylating epothilones |
EP2030618A2 (en) | 2002-01-14 | 2009-03-04 | Novartis AG | Combinations comprising epothilones and anti-metabolites |
US7211593B2 (en) | 2002-03-12 | 2007-05-01 | Bristol-Myers Squibb Co. | C12-cyano epothilone derivatives |
WO2003078411A1 (en) | 2002-03-12 | 2003-09-25 | Bristol-Myers Squibb Company | C3-cyano epothilone derivatives |
US6936628B2 (en) | 2002-04-04 | 2005-08-30 | Bristol-Myers Squibb Company | Oral administration of epothilones |
US7053069B2 (en) | 2002-05-15 | 2006-05-30 | Bristol-Myers Squibb Company | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
US7008936B2 (en) | 2002-06-14 | 2006-03-07 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US7767432B2 (en) | 2002-09-23 | 2010-08-03 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and x-ray crystal structures of epothilone B |
USRE42191E1 (en) | 2002-09-23 | 2011-03-01 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B |
US7172884B2 (en) | 2002-09-23 | 2007-02-06 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and x-ray crystal structures of epothilone B |
EP2280014A3 (en) * | 2002-09-23 | 2011-08-03 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B |
JP2006500031A (en) * | 2002-09-23 | 2006-01-05 | ブリストル−マイヤーズ スクイブ カンパニー | Method for producing, isolating and purifying epothilone B and X-ray crystal structure of epothilone B |
EP2280014A2 (en) | 2002-09-23 | 2011-02-02 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B |
EP2287168A2 (en) | 2002-09-23 | 2011-02-23 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B |
EP1542998A4 (en) * | 2002-09-23 | 2007-01-31 | Bristol Myers Squibb Co | Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b |
US7241899B2 (en) | 2002-09-23 | 2007-07-10 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B |
EP2287168A3 (en) * | 2002-09-23 | 2011-03-16 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B |
EP1542998A2 (en) * | 2002-09-23 | 2005-06-22 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b |
WO2005030767A1 (en) * | 2003-09-26 | 2005-04-07 | Wolfgang Richter | Novel macrocycles for treating tumor diseases |
US7807710B2 (en) | 2003-09-26 | 2010-10-05 | R&D-Biopharmaceuticals Gmbh | Macrocycles for the treatment of cancer |
US7932031B2 (en) | 2004-11-30 | 2011-04-26 | Bristol-Myers Squibb Company | Methods for determining sensitivity to microtubule-stabilizing agents comprising ixabepilone by measuring the level of estrogen receptor 1 |
CN1312286C (en) * | 2005-10-19 | 2007-04-25 | 华南理工大学 | Method for highly-effective producing epothilone using myxobacteria sorangium cellulosum |
WO2007117439A2 (en) | 2006-03-31 | 2007-10-18 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
US8143415B2 (en) | 2007-05-25 | 2012-03-27 | Bristol-Myers Squibb Company | Processes for making epothilone compounds and analogs |
US8299266B2 (en) | 2007-05-25 | 2012-10-30 | Bristol-Myers Squibb Company | Processes for making epothilone compounds and analogs |
EP2065054A1 (en) | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Combinations comprising a prostaglandin and uses thereof |
EP2070521A1 (en) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Surface-modified nanoparticles |
DE102007059752A1 (en) | 2007-12-10 | 2009-06-18 | Bayer Schering Pharma Aktiengesellschaft | Functionalized solid polymer nanoparticles containing epothilones |
EP2241566A1 (en) * | 2008-02-01 | 2010-10-20 | Zhejiang Hisun Pharmaceutical Co. Ltd. | A method for the separation and purification of epothilones |
EP2241566A4 (en) * | 2008-02-01 | 2011-06-15 | Zhejiang Hisun Pharm Co Ltd | A method for the separation and purification of epothilones |
WO2010040252A1 (en) * | 2008-10-06 | 2010-04-15 | 山东大学 | Epothilone glycoside compounds, compositions containing epothilone glycoside compounds as active components and uses thereof |
EP2210584A1 (en) | 2009-01-27 | 2010-07-28 | Bayer Schering Pharma Aktiengesellschaft | Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer |
EP3566719A1 (en) | 2010-05-18 | 2019-11-13 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
US8618146B2 (en) | 2011-01-03 | 2013-12-31 | Dr. Reddy's Laboratories Limited | Epothilone compound formulations |
CN103145722A (en) * | 2013-03-05 | 2013-06-12 | 福建省微生物研究所 | Method for separating and purifying epothilone by high-speed counter-current chromatography |
WO2015024884A1 (en) * | 2013-08-19 | 2015-02-26 | Sandoz Ag | Method for the purifiction of epothilones via crystallization |
Also Published As
Publication number | Publication date |
---|---|
DE4138042A1 (en) | 1993-05-27 |
DE4138042C2 (en) | 1993-10-14 |
AU2943792A (en) | 1993-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE4138042C2 (en) | Epothilones, their production processes and agents containing these compounds | |
EP1367057B1 (en) | Epothilones E and F | |
DE19638870B4 (en) | Tubulysins, methods for their production and agents containing them | |
DE2124711A1 (en) | ||
EP0282455A2 (en) | Method for the preparation of a macrocyclic compound | |
EP0337152A1 (en) | Furans and lactones from streptomycetes, process for their preparation and their use | |
DE2921085C2 (en) | ||
DD202047A5 (en) | PROCESS FOR PREPARING THE MAKROLIDE 20-DIHYDRO-20,23-DIDEOXYTYLONOLIDE | |
EP0358606A2 (en) | Microbiological method for the preparation of agrochemically useful macrocyclic lactone derivatives with a microbicidal activity | |
DE4211056C1 (en) | Spiran heterocyclic deriv. for controlling fungi and bacteria uncontrollable - prepd. by fermenting Sorangium e.g. Polyangium cellulosum in medium contg. carbon and nitrogen sources and mineral salts in adsorber resin, and eluting | |
DE19630980B4 (en) | Etnangien, production, use and production strain sorangium cellulosum DSM 11 028 | |
EP0272668B1 (en) | Amycin and its derivatives, process for their production and their use | |
DE2659180C2 (en) | Antibiotic derivative of the substance SF-1540 and process for its preparation | |
EP0339442A2 (en) | Angucyclinones from streptomyces, process to obtain them and their use | |
DE3141168A1 (en) | ANTHRACYCLINE COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THE SAME | |
DE2921052C2 (en) | ||
DE19636721A1 (en) | Antibiotic and antitumor compound, manufacturing process, agent and DSM 11 071 | |
WO1991000860A1 (en) | Nitrogenous ambruticines, process for obtaining them and their use | |
WO1999047523A1 (en) | A and b apicularene | |
DE1617803A1 (en) | A previously unknown antibiotic and a process for its production | |
DE3823067A1 (en) | Chemical compound with antibiotic activity and preparation process | |
DE3840519A1 (en) | NEW ANGUCYCLINONE FROM STREPTOMYCETES, PROCESS FOR THEIR PREPARATION AND THEIR USE | |
DE2510868C3 (en) | Nanaomycin A and process for the preparation of the antibiorica nanaomycin A and nanaomycin B. | |
DE4305486A1 (en) | Icumazoles and preparation processes | |
DE19607702A1 (en) | Heterocyclic compounds, manufacturing processes and agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI HU JP KR NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |